Subscribe to MDT Magazine News

Summary Box: Aetna's 1Q profit, 2011 forecast grow

April 28, 2011 10:45 am | by The Associated Press | Comments

THE RESULTS: Health insurer Aetna Inc. said Thursday its first-quarter net income rose 4 percent to $586 million, or $1.50 per share. Revenue fell 3 percent to $8.39 billion. Adjusted earnings were $1.43 per share.THE EXPECTATIONS: Analysts surveyed by FactSet forecast, on average, earnings of 96...

Zimmer Holdings 1Q profit rises 2 percent

April 28, 2011 9:45 am | by The Associated Press | Comments

Orthopedic implant maker Zimmer Holdings Inc. said Thursday its first-quarter profit rose 2 percent on higher sales of reconstructive, dental and other products.The company reported net income of $208.9 million, or $1.08 per share, up from $205.4, or $1.01 per share, a year earlier. Sales rose...

Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations

April 28, 2011 9:36 am | by Bio-Medicine.Org | Comments

BETHLEHEM, Pa., April 28, 2011 /- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Celanese EVA Performance Polymers, a leading supplier of ethylene vinyl acetate (EVA) into pharmaceutical applications, are working together to streamline the development of drug-eluting...


Bill & Melinda Gates Foundation Funds Bold Ideas Including Empty Virus Shells to Improve Polio Immunity, Dirt-Charged Cell Phones, and Fertilizer Pellets that Reduce Healt...

April 28, 2011 9:35 am | by Bio-Medicine.Org | Comments

SEATTLE, April 28, 2011 /-The Bill & Melinda Gates Foundation today announced 88 new winners of US$100,000 each to support innovative research that has the potential to dramatically improve lives in some of the world's poorest countries. The funding, made possible through the Grand...


NEW Ocudoxâ„¢ Convenience Kit Now Available in Pharmacies for Immediate Dispensing

April 28, 2011 9:35 am | by Bio-Medicine.Org | Comments

RICHMOND, Texas, April 28, 2011 /- OCuSOFT, Inc., an ophthalmic research, development, and supply company is pleased to announce the availability of prescription-only (Rx) Ocudox™ Convenience Kit for immediate dispensing at most retail pharmacies including, but not limited to:...


Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration

April 28, 2011 9:34 am | by Bio-Medicine.Org | Comments

CLEVELAND, April 28, 2011 /- A new study published online today in The New England Journal of Medicine ( NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD)....


Bayer HealthCare to Sponsor World Federation of Hemophilia Global Training Program and Donate Kogenate® FS, Antihemophilic Factor (Recombinant), Commercially Valued At More T...

April 28, 2011 9:33 am | by Bio-Medicine.Org | Comments

MONTVILLE, N.J., and MONTREAL, April 28, 2011 /- Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia (WFH) are announcing a three-year extension of Bayer's sponsorship agreement with WFH.  The agreement calls for Bayer to serve as sole sponsor of WFH's...


Mystery solved: How sickle hemoglobin protects against malaria

April 28, 2011 8:38 am | by EurekAlert | Comments

(Instituto Gulbenkian de Ciencia) At latest issue of the journal Cell, a study challenges the currently heldviews and unravel the molecular mechanism whereby sickle cell hemoglobin confers a survival advantage against malaria, the disease caused by Plasmodium infection. These...


IRIDEX Announces First Quarter 2011 Conference Call and Release Date

April 28, 2011 8:34 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., April 28, 2011 /- IRIDEX Corporation (NASDAQ: IRIX ) today announced that it will release its first quarter 2011 financial results after the market closes on Thursday, May 5, 2011.  In conjunction with the release, the Company will host a conference call with...


Dentsply 1Q profit rises 12 percent

April 28, 2011 7:45 am | by The Associated Press | Comments

Dentsply International Inc. said Thursday its first-quarter net income rose 12 percent on higher sales of dental products.But, the company set new, lower profit guidance for 2011 after considering supply chain disruptions in the Japanese market in the aftermath of the March 11 earthquake and...

imX Learning Labs to Provide Guidance, Foster Partnerships for the Future of Manufacturing

April 28, 2011 7:39 am | by Society of Manufacturing Engineers | Comments

LAS VEGAS — April 28, 2011 — Manufacturers from across the country will participate in a one-of-a-kind series of “Learning Labs” this fall as part of the Interactive Manufacturing Experience (imX). The event features an unprecedented industry summit to chart a new course for...

Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estima...

April 28, 2011 6:38 am | by Bio-Medicine.Org | Comments

LAWRENCE, Mass., April 28, 2011 /- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today commented on study results presented by the Chronic Disease Research Group (CDRG) showing daily home hemodialysis with the NxStage System One is...


Zentrip Offers a 'Sea Change' in Stopping the Distress from Motion Sickness

April 28, 2011 6:37 am | by Bio-Medicine.Org | Comments

TORRANCE, Calif., April 28, 2011 /- There's a sea change sweeping across the country on how people treat themselves for motion sickness. No longer do they need to carry bottles of liquid and slow-acting pills on their travels, worrying about getting seasick or motion sickness in a car,...


Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop

April 28, 2011 6:37 am | by Bio-Medicine.Org | Comments

SOUTH SAN FRANCISCO, Calif., April 28, 2011 /- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in...


SUPERA VERITAS® Receives Regulatory Approval in Australia

April 28, 2011 6:35 am | by Bio-Medicine.Org | Comments

WEBSTER, Texas, April 28, 2011 /- IDEV Technologies, Inc. (IDEV) today announced the firm has received approval from the Therapeutic Goods Administration (TGA), Australia's regulatory agency for medical drugs and devices, for the SUPERA VERITAS® stent system for use in biliary and...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.